Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients With Hypoplastic Left Heart Syndrome (HLHS)
Phase 1
Not yet recruiting
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Drug: Ventrix Bio Extracellular Matrix
Subscribe
First Posted Date
2024-06-17
Last Posted Date
2024-06-17
Lead Sponsor
Emory University
Target Recruit Count
12
Registration Number
NCT06461676
Locations
🇺🇸
Children's Healthcare of Altanta, Atlanta, Georgia, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy